A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine‑resistant breast cancer cells

  • Authors:
    • Ou Huang
    • Zuoquan Xie
    • Weili  Zhang
    • Ying  Lou
    • Yan  Mao
    • Hongchun Liu
    • Min Jiang
    • Kunwei Shen
  • View Affiliations

  • Published online on: June 12, 2014     https://doi.org/10.3892/or.2014.3249
  • Pages: 627-634
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A771726, an orally available anti-inflammatory agent, has been approved for the treatment of multiple sclerosis by diminishing entire inflammatory responses through multiple signaling pathways. Recently, a few emerging studies have focused on the potential application of A771726 in cancer therapy, less on the treatment of breast cancer and particularly on overcoming drug resistance in breast cancer. We report here for the first time the cytotoxic activity and drug resistance reversal of A771726 in acquired tamoxifen-resistant breast cancer cell line MCF-7/LCC9. We discovered that A771726 treatment showed antiproliferative activities in MCF-7/LCC9 cells, which were even more sensitive to A771726 than their parental tamoxifen-sensitive cells (MCF‑7). A771726 also exerted pro-apoptotic activities and induced cell cycle arrest at the G1 phase. Notably, treatment of A771726 restored the sensitivity of MCF-7/LCC9 cells to tamoxifen. Western blot analysis revealed that A771726 decreased the phosphorylation level of Src, one key driver of tamoxifen resistance. Moreover, in order to comprehensively clarify the mechanisms of A771726 in anti-estrogen-resistant cells, we explored a genome-wide transcriptomic analysis, and showed that A771726 could modulate multiple signaling pathways (e.g. cell cycle, apoptosis, MAPK, metabolism and p53 signaling pathway) and cellular processes (e.g. signal transduction, transcription and cell cycle). Overall, our results indicate that A771726 alone and the combination of A771726 with anti-estrogens may be of therapeutic benefit for ER-positive and endocrine-resistant breast cancer.
View Figures
View References

Related Articles

Journal Cover

August-2014
Volume 32 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang O, Xie Z, Zhang W, Lou Y, Mao Y, Liu H, Jiang M and Shen K: A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine‑resistant breast cancer cells. Oncol Rep 32: 627-634, 2014
APA
Huang, O., Xie, Z., Zhang, W., Lou, Y., Mao, Y., Liu, H. ... Shen, K. (2014). A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine‑resistant breast cancer cells. Oncology Reports, 32, 627-634. https://doi.org/10.3892/or.2014.3249
MLA
Huang, O., Xie, Z., Zhang, W., Lou, Y., Mao, Y., Liu, H., Jiang, M., Shen, K."A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine‑resistant breast cancer cells". Oncology Reports 32.2 (2014): 627-634.
Chicago
Huang, O., Xie, Z., Zhang, W., Lou, Y., Mao, Y., Liu, H., Jiang, M., Shen, K."A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine‑resistant breast cancer cells". Oncology Reports 32, no. 2 (2014): 627-634. https://doi.org/10.3892/or.2014.3249